HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Signal Recognition Particle

A cytosolic ribonucleoprotein complex that acts to induce elongation arrest of nascent presecretory and membrane proteins until the ribosome becomes associated with the rough endoplasmic reticulum. It consists of a 7S RNA and at least six polypeptide subunits (relative molecular masses 9, 14, 19, 54, 68, and 72K).
Also Known As:
Particle, Signal Recognition; Recognition Particle, Signal; SRP (Signal Recognition Particle)
Networked: 82 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Suzuki, Shigeaki: 7 articles (01/2015 - 08/2011)
2. Kuwana, Masataka: 6 articles (09/2015 - 09/2005)
3. Oddis, Chester V: 6 articles (07/2015 - 01/2004)
4. Nishino, Ichizo: 5 articles (01/2015 - 08/2011)
5. Fertig, Noreen: 4 articles (07/2015 - 01/2004)
6. Hayashi, Yukiko K: 4 articles (01/2015 - 08/2011)
7. Targoff, Ira N: 4 articles (01/2013 - 07/2005)
8. Benveniste, Olivier: 3 articles (03/2015 - 05/2006)
9. Suzuki, Norihiro: 3 articles (01/2015 - 06/2012)
10. Boyer, Olivier: 3 articles (05/2014 - 05/2006)

Related Diseases

1. Muscular Diseases (Myopathy)
2. Myositis (Idiopathic Inflammatory Myopathies)
3. Neoplasms (Cancer)
4. Dermatomyositis (Dermatopolymyositis)
09/01/2005 - "Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). "
01/01/2009 - "To elucidate the clinical and histopathological features associated with autoantibodies to the signal recognition particle (SRP), we have studied 23 Japanese patients with this specificity among 3,500 patients with polymyositis/dermatomyositis and other connective tissue diseases. "
11/01/1991 - "In idiopathic inflammatory myopathy (IIM; or, polymyositis/dermatomyositis), the myositis-specific autoantibodies anti-Jo-1 and anti-signal recognition particle (anti-SRP), appear to define clinically and immunogenetically distinct groups of patients. "
12/25/1998 - "We report that the 72-kDa signal recognition particle (SRP) protein, a rare target of autoantibodies found in the serum of patients with dermatomyositis and systemic lupus erythematosus, is rapidly cleaved in Jurkat T cells treated with apoptotic (i.e. "
11/01/2011 - "Pathologic classification categories include immune myopathies with perimysial pathology (IMPP), a group that can be associated with antisynthetase antibodies; myovasculopathies, including childhood dermatomyositis; immune polymyopathies, active myopathies with little inflammation such as the myopathy with signal recognition particle antibodies; immune myopathies with endomysial pathology (IM-EP), illustrated by brachio-cervical inflammatory myopathy (BCIM); histiocytic inflammatory myopathies, like sarcoid myopathy; and inflammatory myopathies with vacuoles, aggregates and mitochondrial pathology (IM-VAMP), which have inclusion body myositis as a pathologic subtype and are poorly treatable. "
5. Interstitial Lung Diseases (Interstitial Lung Disease)
01/01/2010 - "[A case of interstitial pneumonia with anti-signal recognition particle (SRP) antibody without myopathy]."
05/01/2008 - "Anti-signal recognition particle (anti-SRP) is a myositis-specific autoantibody that is linked to a severe polymyositis (PM) associated with interstitial lung disease (ILD) and esophageal dysmotility in adults. "
10/01/2007 - "Diffuse cutaneous type, erosive esophagitis, and myositis were more common in group 1 than in group 2 (p = 0.007, 0.003, and 0.003, respectively) or group 3 (p = 0.04, 0.002, and 0.01, respectively), whereas interstitial lung disease (ILD) was more frequent in group 2 (p = 0.005) and group 3 (p = 0.02) versus group 1. Antinuclear antibodies showed a nucleolar pattern significantly more frequently in group 1. Myositis-related autoantibodies, including anti-U1RNP, anti-U3RNP, anti-Ku, and anti-signal recognition particle antibodies, were observed in 57% of group 1. Our findings strongly suggest the existence of a subgroup of SSc patients with severe GIT involvement in the early stage. "
04/01/1992 - "Antibodies to aminoacyl transfer RNA (tRNA) synthetases and the signal recognition particle (SRP) were found to be specific for PM/DM: PM/DM patients with antibodies to 3 aminoacyl-tRNA synthetases (histidyl, threonyl, and glycyl) appeared to form a distinct clinical subset, associated with chronic interstitial lung disease, polyarthritis, and myositis, while 3 patients with antibodies that bound the SRP had severe myositis that was resistant to corticosteroid therapy. "
09/01/2014 - "Two investigators independently extracted data on study design, patient characteristics, and clinical features (interstitial lung disease [ILD], fever, mechanic's hands [MH], Raynaud's phenomenon [RPh], arthralgia, sclerodactyly, cancer and dermatomyositis-specific rash) according to the presence of myositis-specific (anti-aminoacyl-transfer RNA synthetase [ARS], anti-signal recognition particle [anti-SRP] and anti-Mi2) and myositis-associated (anti-PM/Scl, anti-U1-RNP and anti-Ku) autoantibodies. "

Related Drugs and Biologics

1. Antibodies
2. rituximab (Mabthera)
3. Prednisone (Sone)
4. Autoantibodies
5. Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)
6. Ligases
7. Transfer RNA (tRNA)
8. Oxidoreductases
9. Antigens
10. 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)

Related Therapies and Procedures

1. Plasma Exchange